Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 1/2009

01-12-2009 | Short Report

Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) as a cause of liver disease in infants in the UK

Authors: T. Hutchin, M. A. Preece, C. Hendriksz, A. Chakrapani, V. McClelland, F. Okumura, Y.-Z. Song, M. Iijima, K. Kobayashi, T. Saheki, P. McKiernan, U. Baumann

Published in: Journal of Inherited Metabolic Disease | Special Issue 1/2009

Login to get access

Summary

Citrin deficiency is a disorder with two phenotypes: neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), and adult-onset type II citrullinaemia (CTLN2). NICCD presents in the first few weeks of life with prolonged cholestasis and metabolic abnormalities including aminoacidaemia (notably citrulline, tyrosine, threonine, arginine and methionine) and galactosuria. Symptoms resolve within the first year of life, thus making a diagnosis difficult after this time. Although patients subsequently remain generally healthy, some may develop more severe symptoms of CTLN2, characterized by neurological changes, one or more decades later. To date more than 400 cases have been reported, almost all from East Asia (mainly Japan). Here we describe the first two cases of NICCD in infants from the UK, one of caucasian origin and one of Pakistani origin. Both showed typical clinical and biochemical changes with a diagnosis confirmed by the presence of previously unreported mutations in the SLC25A13 gene. The presence of citrin deficiency in other ethnic groups means that NICCD needs to be considered in the diagnosis of any neonate with an unexplained cholestasis. We discuss both the difficulties in diagnosing these patients in populations where very few DNA mutations have been identified and the problems faced in the management of these patients. These findings also raise the possibility of adults with CTLN2 in whom a diagnosis has yet to be made.
Literature
go back to reference Fiermonte G, Soon D, Chaudhuri A, et al (2008) An adult with type 2 citrullinaemia presenting in Europe. N Engl J Med 358:1408–1409PubMedCrossRef Fiermonte G, Soon D, Chaudhuri A, et al (2008) An adult with type 2 citrullinaemia presenting in Europe. N Engl J Med 358:1408–1409PubMedCrossRef
go back to reference Imamura Y, Kobayashi K, Shibatou T, et al (2003) Effectiveness of carbohydrate-restricted diet and arginine granules therapy for adult-onset type II citrullianaemia: a case report of siblings showing homozygous SLC25A13 mutation with and without the disease. Hepatol Res 26:68–72. doi:10.1016/S1386-6346(02)00331-5 PubMedCrossRef Imamura Y, Kobayashi K, Shibatou T, et al (2003) Effectiveness of carbohydrate-restricted diet and arginine granules therapy for adult-onset type II citrullianaemia: a case report of siblings showing homozygous SLC25A13 mutation with and without the disease. Hepatol Res 26:68–72. doi:10.​1016/​S1386-6346(02)00331-5 PubMedCrossRef
go back to reference Kobayashi K, Saheki T (2004) [Molecular basis of citrin deficiency] Seikagaku 76:1543–1549PubMed Kobayashi K, Saheki T (2004) [Molecular basis of citrin deficiency] Seikagaku 76:1543–1549PubMed
go back to reference Saheki T, Kobayashi K (2002) Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD) J Hum Genet 47:333–341. doi:10.1007/s100380200046 PubMedCrossRef Saheki T, Kobayashi K (2002) Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD) J Hum Genet 47:333–341. doi:10.​1007/​s100380200046 PubMedCrossRef
go back to reference Tabata A, Sheng JS, Ushikai M, et al (2008) Identification of 13 novel mutations including a retrotransposal insertion in SLC25A13 gene and frequency of 30 mutations found in patients with citrin deficiency. J Hum Genet 53:534–545. doi:10.1007/s10038-008-0282-2 PubMedCrossRef Tabata A, Sheng JS, Ushikai M, et al (2008) Identification of 13 novel mutations including a retrotransposal insertion in SLC25A13 gene and frequency of 30 mutations found in patients with citrin deficiency. J Hum Genet 53:534–545. doi:10.​1007/​s10038-008-0282-2 PubMedCrossRef
go back to reference Tamamori A, Okano Y, Ozaki H, et al (2002) Neonatal intrahepatic cholestasis caused by citrin deficiency: severe hepatic dysfunction in an infant requiring liver transplantation. Eur J Pediatr 161:609–613. doi:10.1007/s00431-002-1045-2 PubMedCrossRef Tamamori A, Okano Y, Ozaki H, et al (2002) Neonatal intrahepatic cholestasis caused by citrin deficiency: severe hepatic dysfunction in an infant requiring liver transplantation. Eur J Pediatr 161:609–613. doi:10.​1007/​s00431-002-1045-2 PubMedCrossRef
go back to reference Tsuboi Y, Fujino Y, Kobayashi K, et al (2001) High serum pancreatic secretory trypsin inhibitor before onset of type II citrullinemia. Neurology. 57:933PubMedCrossRef Tsuboi Y, Fujino Y, Kobayashi K, et al (2001) High serum pancreatic secretory trypsin inhibitor before onset of type II citrullinemia. Neurology. 57:933PubMedCrossRef
go back to reference Yasuda T, Yamaguchi N, Kobayashi K, et al (2000) Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 patients with adult-onset type II citrullinemia. Hum Genet 107:537–45. doi:10.1007/s004390000430 PubMedCrossRef Yasuda T, Yamaguchi N, Kobayashi K, et al (2000) Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 patients with adult-onset type II citrullinemia. Hum Genet 107:537–45. doi:10.​1007/​s004390000430 PubMedCrossRef
Metadata
Title
Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) as a cause of liver disease in infants in the UK
Authors
T. Hutchin
M. A. Preece
C. Hendriksz
A. Chakrapani
V. McClelland
F. Okumura
Y.-Z. Song
M. Iijima
K. Kobayashi
T. Saheki
P. McKiernan
U. Baumann
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue Special Issue 1/2009
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-009-1116-x

Other articles of this Special Issue 1/2009

Journal of Inherited Metabolic Disease 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine